Darby R. Schmidt, Ph.D.

Darby Schmidt is the Vice President of Programs and Drug Discovery at Sonata Therapeutics. Darby brings 20 years of leadership and experience to Sonata where she oversees the development of the company’s small molecule programs.

Previously, Darby led chemistry and preclinical development at Caraway Therapeutics. Prior to this role, she was a Program Director for Quartet Medicine and a Principal Scientist at Syros Pharmaceuticals. Darby began her career as a medicinal chemist at Merck.

Darby received her B.A. in Chemistry from Princeton University and her Ph.D. from Harvard University.